



*This file was downloaded after successfully submitting access request for the OASIS projects. I understand that access to OASIS-1 and OASIS-2 files are now available for download at <https://www.oasis-brains.org/#data>. I will receive an email from OASIS administrators with access to a project on [central.xnat.org](http://central.xnat.org) if my application is accepted for OASIS-3 or OASIS-4.*

## Data Use Agreement

The OASIS data are distributed to the greater scientific community under the following terms:

1. You will not attempt to establish the identity of or to make contact with any of the included human participants. This includes but is not limited to, facial recognition and 3D facial rendering.
  
2. You will acknowledge the use of OASIS data and data derived from OASIS data when publicly presenting any results or algorithms that benefitted from their use. Papers, book chapters, books, posters, oral presentations, and all other printed and digital presentations of results derived from OASIS data should contain the following:
  - a. **Acknowledgments:** "Data were provided [in part] by OASIS [insert appropriate OASIS source info]"
    - i. OASIS: Cross-Sectional: Principal Investigators: D. Marcus, R. Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
    - ii. OASIS: Longitudinal: Principal Investigators: D. Marcus, R. Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
    - iii. OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.

- iv. OASIS-3 AV1451: Principal Investigators: T. Benzinger, J. Morris; AW00006993. AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
  - v. OASIS-4: Clinical Cohort: Principal Investigators: T. Benzinger, L. Koenig, P. LaMontagne
- b. **Citation:** The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes. An annotated and current list of OASIS publications is available at <http://www.oasis-brains.org>.
- i. OASIS: Cross-Sectional: <https://doi.org/10.1162/jocn.2007.19.9.1498>
  - ii. OASIS: Longitudinal: <https://doi.org/10.1162/jocn.2009.21407>
  - iii. OASIS-3: Longitudinal Multimodal Neuroimaging: <https://doi.org/10.1101/2019.12.13.19014902>
  - iv. OASIS-4: Clinical Cohort: <https://doi.org/10.1016/j.nicl.2020.102248>
- c. All proposed publications or presentations using Florbetapir F18 (AV45) or Flortaucipir F18 (AV1451) PET data must be submitted to Avid Radiopharmaceuticals for review and comment thirty days prior to such presentation or publication for review of intellectual property interests. See Imaging Data Dictionary for contact information and details.
- i. Please reference OASIS-brains.org and Washington University (Drs. Morris and Benzinger) in your email. Contacts:
    - 1. Elizabeth DiPardo [dipardo@avidrp.com](mailto:dipardo@avidrp.com)
    - 2. Patricia Aldea Stevenson <[stevenson@avidrp.com](mailto:stevenson@avidrp.com)>
3. You agree to provide the Knight ADRC upon request with information on your use of OASIS data
4. Failure to abide by these data use terms may result in termination of your right to access and use OASIS data.

**OASIS Contact:** [oasis-brains@nrg.wustl.edu](mailto:oasis-brains@nrg.wustl.edu)